NO20042584L - Dibenzylaminforbindelser og farmasoytisk anvendelse derav - Google Patents

Dibenzylaminforbindelser og farmasoytisk anvendelse derav

Info

Publication number: NO20042584L
Authority: NO; Norway
Prior art keywords: alkyl group; hydrogen atom; pharmaceutical use; halogen atom; halogen
Prior art date: 2002-08-30

Application number

NO20042584A

Other languages

English (en)

Other versions

NO328886B1 (no

Inventor

Hisashi Shinkai

Kimiya Maeda

Hironobu Nagamori

Hiroshi Nakamura

Yasunori Suzuki

Original Assignee

Japan Tobacco Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-08-30

Filing date

2004-06-18

Publication date

2004-06-18

2004-06-18 Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc

2004-06-18 Publication of NO20042584L publication Critical patent/NO20042584L/no

2010-06-07 Publication of NO328886B1 publication Critical patent/NO328886B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
- C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
- C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Obesity (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Solid Fuels And Fuel-Associated Substances (AREA)

NO20042584A 2002-08-30 2004-06-18 Dibenzylaminforbindelser, anvendelse av forbindelsene, farmasoytiske midler omfattende forbindelsene samt CETP-aktivitetsinhibitor NO328886B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2002255604		2002-08-30
JP2003107161		2003-04-10
PCT/JP2003/011041 WO2004020393A1 (ja)	2002-08-30	2003-08-29	ジベンジルアミン化合物及びその医薬用途

Publications (2)

Publication Number	Publication Date
NO20042584L true NO20042584L (no)	2004-06-18
NO328886B1 NO328886B1 (no)	2010-06-07

Family

ID=31980551

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042584A NO328886B1 (no)	2002-08-30	2004-06-18	Dibenzylaminforbindelser, anvendelse av forbindelsene, farmasoytiske midler omfattende forbindelsene samt CETP-aktivitetsinhibitor

Country Status (24)

Country	Link
US (2)	US7332514B2 (no)
EP (2)	EP1533292B1 (no)
KR (1)	KR100634195B1 (no)
CN (1)	CN1289467C (no)
AT (1)	ATE353870T1 (no)
AU (1)	AU2003261826B2 (no)
BR (1)	BR0306208A (no)
CA (1)	CA2464846C (no)
CY (1)	CY1106425T1 (no)
CZ (1)	CZ2004627A3 (no)
DE (1)	DE60311821T2 (no)
DK (1)	DK1533292T3 (no)
ES (1)	ES2277142T3 (no)
IL (2)	IL161559A0 (no)
MX (1)	MXPA04005350A (no)
NO (1)	NO328886B1 (no)
NZ (1)	NZ532494A (no)
PT (1)	PT1533292E (no)
RU (1)	RU2293078C2 (no)
SI (1)	SI1533292T1 (no)
SK (1)	SK2332004A3 (no)
TR (1)	TR200401413T1 (no)
WO (1)	WO2004020393A1 (no)
ZA (1)	ZA200403137B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7393652B2 (en) *	2000-05-10	2008-07-01	The Trustees Of Columbia University In The City Of New York	Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) *	2000-05-10	2004-11-18	Marks Andrew Robert	Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US6489125B1 (en) *	2000-05-10	2002-12-03	The Trustees Of Columbia University In The City Of New York	Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US8022058B2 (en)	2000-05-10	2011-09-20	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) *	2000-05-10	2004-03-11	The Trustees Of Columbia University In The City Of New York	Method for treating and preventing cardiac arrhythmia
US7718644B2 (en) *	2004-01-22	2010-05-18	The Trustees Of Columbia University In The City Of New York	Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) *	2005-08-25	2011-02-01	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
US20060293266A1 (en) *	2000-05-10	2006-12-28	The Trustees Of Columbia	Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
SK2332004A3 (en) *	2002-08-30	2004-12-01	Japan Tobacco Inc	Dibenzylamine compound and medicinal use thereof
US7544678B2 (en) *	2002-11-05	2009-06-09	The Trustees Of Columbia University In The City Of New York	Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
AU2004220548A1 (en)	2003-03-07	2004-09-23	The Trustees Of Columbia University, In The City Of New York	Type 1 ryanodine receptor-based methods
EP2319509A1 (en) *	2003-09-26	2011-05-11	Japan Tobacco, Inc.	Method of Inhibiting remnant lipoprotein production
AU2008201550B2 (en) *	2003-09-26	2011-02-10	Japan Tobacco Inc.	Method of inhibiting remnant lipoprotein production
ES2332051T3 (es) *	2003-10-08	2010-01-25	Eli Lilly And Company	Compuestos y procedimientos para tratar dislipidemia.
US8710045B2 (en) *	2004-01-22	2014-04-29	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the ryanodine receptors
JP4587685B2 (ja) *	2004-03-23	2010-11-24	セントラル硝子株式会社	３−ホルミル−５−トリフルオロメチルベンゾニトリル誘導体とその製造方法
AU2005230915A1 (en) *	2004-03-26	2005-10-20	Eli Lilly And Company	Compounds and methods for treating dyslipidemia
CA2562082C (en)	2004-04-13	2013-06-25	Merck & Co., Inc.	Cetp inhibitors for the treatment and prevention of atherosclerosis
JP2008504266A (ja) *	2004-06-24	2008-02-14	イーライリリーアンドカンパニー	異脂肪血症を治療するための化合物及び方法
MX2007001431A (es) *	2004-08-05	2007-04-02	Hoffmann La Roche	Derivados de indol, de indazol o de indolina.
US9040558B2 (en)	2004-12-31	2015-05-26	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
US8604055B2 (en) *	2004-12-31	2013-12-10	Dr. Reddy's Laboratories Ltd.	Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
WO2007075194A1 (en)	2005-12-28	2007-07-05	Reddy Us Therapeutics, Inc.	Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
US8617604B2 (en)	2005-02-03	2013-12-31	Bend Research, Inc.	Pharmaceutical compositions with enhanced performance
WO2006098394A1 (ja) *	2005-03-14	2006-09-21	Japan Tobacco Inc.	脂質吸収抑制方法および脂質吸収抑制剤
US7704990B2 (en) *	2005-08-25	2010-04-27	The Trustees Of Columbia University In The City Of New York	Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007041494A2 (en) *	2005-09-30	2007-04-12	Merck & Co., Inc.	Cholesteryl ester transfer protein inhibitors
US7935727B2 (en) *	2005-10-19	2011-05-03	Merck Sharp & Dohme Corp.	CETP inhibitors
HRP20160679T1 (hr) *	2005-12-22	2016-07-15	Takeda Pharmaceutical Company Limited	Kruti pripravak koji sadrži senzibilizator inzulina
CA2634833A1 (en) *	2005-12-29	2007-07-05	Novartis Ag	Pyridinyl amine derivatives as inhibitors of cholesteryl ester transfer protein (cetp)
UY30117A1 (es) *	2006-01-31	2007-06-29	Tanabe Seiyaku Co	Compuesto amina trisustituido
PE20071025A1 (es) *	2006-01-31	2007-10-17	Mitsubishi Tanabe Pharma Corp	Compuesto amina trisustituido
US7572823B2 (en) *	2006-02-07	2009-08-11	Hoffmann-La Roche Inc.	Heteroaryl carboxamide compounds
BRPI0707584A2 (pt) *	2006-02-09	2011-05-10	Merck & Co Inc	composiÇço farmacÊutica, uso da composiÇço farmacÊutica, e, formulaÇço farmacÊutica
US7919506B2 (en)	2006-03-10	2011-04-05	Pfizer Inc.	Dibenzyl amine compounds and derivatives
US8383660B2 (en)	2006-03-10	2013-02-26	Pfizer Inc.	Dibenzyl amine compounds and derivatives
TW200808731A (en)	2006-03-30	2008-02-16	Tanabe Seiyaku Co	A process for preparing tetrahydroquinoline derivatives
AR060873A1 (es)	2006-05-10	2008-07-16	Novartis Ag	Derivados biciclicos como inhibidores de cetp
GB0609268D0 (en) *	2006-05-10	2006-06-21	Novartis Ag	Organic compounds
CA2650515A1 (en) *	2006-05-11	2007-11-22	Novartis Ag	Benzylamine derivatives as cetp inhibitors
EP2049493B1 (en) *	2006-07-31	2012-03-21	Cadila Healthcare Limited	Compounds suitable as modulators of hdl
KR100821688B1 (ko)	2006-08-10	2008-04-11	(주)유케이케미팜	암로디핀 라셈화물의 입체이성질체의 분리방법과 그의친수성 약물 및 그의 제조방법
US7750019B2 (en)	2006-08-11	2010-07-06	Kowa Company, Ltd.	Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en)	2007-03-13	2010-09-07	Kowa Company, Ltd.	Substituted pyrimidine compounds and their utility as CETP inhibitors
CN101679309B (zh) *	2007-04-13	2012-02-29	兴和株式会社	具有二苄胺结构的新型嘧啶化合物和含有该化合物的药物
JP4834699B2 (ja) *	2007-07-30	2011-12-14	田辺三菱製薬株式会社	医薬組成物
JP4846769B2 (ja) *	2007-07-30	2011-12-28	田辺三菱製薬株式会社	医薬組成物
JP5319457B2 (ja) *	2008-08-25	2013-10-16	興和株式会社	新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
WO2010061621A1 (ja)	2008-11-28	2010-06-03	興和株式会社	ｔｒａｎｓ－｛４－［（アルキルアミノ）メチル］シクロヘキシル｝酢酸エステルの製造方法
AR077208A1 (es)	2009-06-30	2011-08-10	Lilly Co Eli	Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
US9867811B2 (en) *	2011-07-08	2018-01-16	Novartis Ag	Method of treating atherosclerosis in high triglyceride subjects
US9199967B2 (en)	2011-08-18	2015-12-01	Dr. Reddy's Laboratories Ltd.	Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
IN2014CN02290A (no)	2011-09-27	2015-06-19	Reddys Lab Ltd Dr
EP3006430A4 (en)	2013-05-31	2016-11-02	Kowa Co	NOVEL FORM OF A PYRIMIDINE COMPOUND WITH DIBENZYLAMINE STRUCTURE
BR112017003745A2 (pt)	2014-08-29	2017-12-05	Tes Pharma S R L	inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
CN109661238B (zh)	2016-07-27	2023-07-25	哈里斯制药公司	治疗红细胞疾病的治疗组合

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3576830A (en) *	1966-08-12	1971-04-27	Sumitomo Chemical Co	Amides containing sulfur
US4064125A (en) *	1976-10-29	1977-12-20	E. R. Squibb And Sons, Inc.	Substituted amides having antiinflammatory activity
US4473579A (en) *	1982-01-26	1984-09-25	American Cyanamid Company	Antiatherosclerotic tetrasubstituted ureas and thioureas
US4623662A (en) *	1985-05-23	1986-11-18	American Cyanamid Company	Antiatherosclerotic ureas and thioureas
US5446207A (en)	1993-09-01	1995-08-29	Harbor Branch Oceanographic Institution, Inc.	Anti-dyslipidemic agents
FI964342A0 (fi)	1994-04-29	1996-10-28	Sanofi Winthrop Inc	Halogeenimetyyliamideja IL-1beta-proteaasi-inhibiittoreina
CA2200981A1 (en)	1994-10-04	1996-04-11	Hisashi Takasugi	Urea derivatives and their use as acat-inhibitors
US5834514A (en) *	1995-05-30	1998-11-10	Vertex Pharmaceuticals, Incorporated	Halomethyl amides as IL-1β protease inhibitors
GB9526560D0 (en)	1995-12-27	1996-02-28	Bayer Ag	Use of 2-Amino-Heterocycles
AR008789A1 (es)	1996-07-31	2000-02-23	Bayer Corp	Piridinas y bifenilos substituidos
JP2894445B2 (ja) *	1997-02-12	1999-05-24	日本たばこ産業株式会社	Ｃｅｔｐ活性阻害剤として有効な化合物
RU2176999C2 (ru) *	1997-10-02	2001-12-20	Санкио Компани, Лимитед	Производные амидокарбоновой кислоты, фармацевтическая композиция на их основе и способ снижения глюкозы в крови
AU753540B2 (en) *	1998-03-05	2002-10-24	Agouron Pharmaceuticals, Inc.	Non-peptide GnRH agents
SE9802209D0 (sv)	1998-06-22	1998-06-22	Astra Pharma Inc	Novel compounds
US6197786B1 (en)	1998-09-17	2001-03-06	Pfizer Inc	4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147090A (en)	1998-09-17	2000-11-14	Pfizer Inc.	4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
AU6161099A (en) *	1998-09-25	2000-04-17	Monsanto Company	Substituted n-aliphatic-n-aromatic (tertiary)-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
EP1589000A3 (en) *	1998-09-25	2006-03-15	Monsanto Company	(R)-Chiral halogenated 1-substitutedamino-(N+1)-alkanols useful for inhibiting cholesteryl ester transfer protein activity
KR20020014797A (ko)	1999-05-17	2002-02-25	한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느	글루카곤 길항제/역 아고니스트
UA73307C2 (uk)	1999-08-05	2005-07-15	Куміаі Кемікал Індастрі Ко., Лтд.	Похідна карбамату і фунгіцид сільськогосподарського/садівницького призначення
CO5271716A1 (es)	1999-11-30	2003-04-30	Pfizer Prod Inc	Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
RU2295520C2 (ru) *	2002-07-03	2007-03-20	Ф.Хоффманн-Ля Рош Аг	ПРОИЗВОДНЫЕ ОКСАЗОЛА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ СЕНСИБИЛИЗАТОРОВ ИНСУЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АКТИВИРУЮЩИМ ДЕЙСТВИЕМ В ОТНОШЕНИИ PRARα И/ИЛИ PRARγ
SK2332004A3 (en) *	2002-08-30	2004-12-01	Japan Tobacco Inc	Dibenzylamine compound and medicinal use thereof

2003
- 2003-08-29 SK SK233-2004A patent/SK2332004A3/sk not_active Application Discontinuation
- 2003-08-29 US US10/503,185 patent/US7332514B2/en not_active Expired - Fee Related
- 2003-08-29 DE DE60311821T patent/DE60311821T2/de not_active Expired - Lifetime
- 2003-08-29 CA CA2464846A patent/CA2464846C/en not_active Expired - Fee Related
- 2003-08-29 KR KR1020047010002A patent/KR100634195B1/ko not_active Expired - Fee Related
- 2003-08-29 IL IL16155903A patent/IL161559A0/xx unknown
- 2003-08-29 ES ES03791414T patent/ES2277142T3/es not_active Expired - Lifetime
- 2003-08-29 TR TR2004/01413T patent/TR200401413T1/xx unknown
- 2003-08-29 AU AU2003261826A patent/AU2003261826B2/en not_active Ceased
- 2003-08-29 CZ CZ2004627A patent/CZ2004627A3/cs unknown
- 2003-08-29 PT PT03791414T patent/PT1533292E/pt unknown
- 2003-08-29 BR BR0306208-2A patent/BR0306208A/pt not_active IP Right Cessation
- 2003-08-29 NZ NZ532494A patent/NZ532494A/xx not_active IP Right Cessation
- 2003-08-29 SI SI200330767T patent/SI1533292T1/sl unknown
- 2003-08-29 CN CNB038023830A patent/CN1289467C/zh not_active Expired - Fee Related
- 2003-08-29 RU RU2004119546/04A patent/RU2293078C2/ru not_active IP Right Cessation
- 2003-08-29 EP EP03791414A patent/EP1533292B1/en not_active Expired - Lifetime
- 2003-08-29 EP EP07003011A patent/EP1829858A3/en not_active Withdrawn
- 2003-08-29 AT AT03791414T patent/ATE353870T1/de active
- 2003-08-29 DK DK03791414T patent/DK1533292T3/da active
- 2003-08-29 WO PCT/JP2003/011041 patent/WO2004020393A1/ja not_active Ceased
2004
- 2004-04-22 IL IL161559A patent/IL161559A/en not_active IP Right Cessation
- 2004-04-23 ZA ZA2004/03137A patent/ZA200403137B/en unknown
- 2004-06-03 MX MXPA04005350A patent/MXPA04005350A/es active IP Right Grant
- 2004-06-18 NO NO20042584A patent/NO328886B1/no not_active IP Right Cessation
2007
- 2007-03-30 CY CY20071100447T patent/CY1106425T1/el unknown
- 2007-11-13 US US11/939,359 patent/US7807701B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
SK2332004A3 (en)	2004-12-01
HK1077567A1 (en)	2006-04-13
AU2003261826A1 (en)	2004-03-19
IL161559A0 (en)	2004-09-27
EP1829858A3 (en)	2007-10-03
CA2464846A1 (en)	2004-03-11
CY1106425T1 (el)	2011-10-12
NZ532494A (en)	2006-03-31
RU2293078C2 (ru)	2007-02-10
DE60311821D1 (de)	2007-03-29
CN1617850A (zh)	2005-05-18
EP1533292A1 (en)	2005-05-25
KR20040075908A (ko)	2004-08-30
PT1533292E (pt)	2007-05-31
IL161559A (en)	2009-12-24
CA2464846C (en)	2010-04-06
SI1533292T1 (sl)	2007-08-31
EP1533292A4 (en)	2005-11-02
ES2277142T3 (es)	2007-07-01
US20050059810A1 (en)	2005-03-17
KR100634195B1 (ko)	2006-10-16
ZA200403137B (en)	2005-06-29
MXPA04005350A (es)	2004-09-27
BR0306208A (pt)	2004-10-13
NO328886B1 (no)	2010-06-07
EP1829858A2 (en)	2007-09-05
TR200401413T1 (tr)	2005-06-21
AU2003261826B2 (en)	2006-02-02
ATE353870T1 (de)	2007-03-15
US20080146620A1 (en)	2008-06-19
CZ2004627A3 (cs)	2004-10-13
US7332514B2 (en)	2008-02-19
RU2004119546A (ru)	2005-08-10
CN1289467C (zh)	2006-12-13
DE60311821T2 (de)	2007-10-31
WO2004020393A1 (ja)	2004-03-11
EP1533292B1 (en)	2007-02-14
DK1533292T3 (da)	2007-06-04
US7807701B2 (en)	2010-10-05

Publication	Publication Date	Title
NO20042584L (no)	2004-06-18	Dibenzylaminforbindelser og farmasoytisk anvendelse derav
MXPA06001274A (es)	2006-04-11	Compuestos novedosos que poseen actividad inhibitoria contra transporador dependiente de sodio.
BR0315405A (pt)	2005-08-09	Compostos inibidores da integrase tricìclica pré-organizados
TW200510440A (en)	2005-03-16	Novel compounds
MX2009012283A (es)	2009-11-25	Derivado heterociclico que contiene nitrogeno que tiene actividad inhibitoria de 11beta-hidroxiesteroide-deshidrogenasa tipo 1.
HUP0402376A2 (hu)	2005-02-28	Imidazol-4-karboxamid-származékok, előállításuk és az ezeket tartalmazó, elhízás kezelésére alkalmas gyógyszerkészítmények
MY139887A (en)	2009-11-30	Tetrahydronaphthyridine derivatives and a process for preparing the same.
AR006619A1 (es)	1999-09-08	Derivados de aminopiridina, composicion farmaceutica que los contien, metodo para elaborar un medicamento, intermediario quimico para la produccionde dichos compuestos y procedimiento para preparar los derivados de aminopiridina
HUT53099A (en)	1990-09-28	Process for producing new tetrahydrobenzimidazole derivatives and pharmaceutical compositions comprising such compounds
DK393486A (da)	1987-02-22	Dihydropyridin-derivater og fremgangsmaade til fremstilling deraf
TW200619212A (en)	2006-06-16	Morpholine derivatives
IL160874A0 (en)	2004-08-31	4-imidazolin-2-one derivatives
TW200517387A (en)	2005-06-01	Compounds exhibiting thrombopoietin receptor agonism
DE60045821D1 (de)	2011-05-19	Derivate von aromatische heterocyclen enthaltende integraseinhibitoren
EA200401077A1 (ru)	2005-06-30	2-оксазоламины и их применение в качестве антагонистов рецептора 5-ht2b
ATE229538T1 (de)	2002-12-15	22r-hydroxycholesta-8,14-diene derivate zur hemmung der meiose
MY139258A (en)	2009-09-30	Carbamoyl-type benzofuran derivatives
EP1908752A4 (en)	2009-09-02	NEW 2-CHINOLO DERIVATIVES
NO955071D0 (no)	1995-12-14	abeo-Ergolin-derivater som 5HT1A-ligander
NO20053302D0 (no)	2005-07-05	Imidazolderivater med affinitet for alfa 2-reseptoraktivitet.
TW200508211A (en)	2005-03-01	2-naphthylimino-1,3-thiazine derivatives

Legal Events

Date	Code	Title	Description
2017-03-20	MM1K	Lapsed by not paying the annual fees